Published in final edited form as:

Immunol Lett. 2007 November 15; 113(2): 117–120.

Immunopathogenesis of hantavirus pulmonary syndrome and hemorrhagic fever with renal syndrome: Do CD8⁺ T cells trigger capillary leakage in viral hemorrhagic fevers?

Masanori Terajima, Daisuke Hayasaka, Ken Maeda, and Francis A. Ennis

Center for Infectious Disease and Vaccine Research, University of Massachusetts Medical School, Worcester, MA, 01655, U.S.A.

Keywords

hantavirus; endothelial cells; cytotoxic T lymphocytes; PD-1; PD-L1; PD-L2; hantavirus pulmonary syndrome; hemorrhagic fever with renal syndrome

There are many viruses known to cause viral hemorrhagic fevers in humans [1]. The mechanisms causing hemorrhage are likely to vary among viruses [2]. Some viruses, such as Marburg virus, are directly cytopathic to infected endothelial cells [3], suggesting infection of endothelial cells alone can cause hemorrhage. On the other hand, there are viruses which infect endothelial cells without causing any cytopathic effects, suggesting the involvement of host immune responses in developing hemorrhage. Typical examples of these include hantaviruses [4–7], which belong to genus *Hantavirus*, family *Bunyaviridae*.

Hantaviruses are RNA viruses possessing a segmented negative-stranded RNA genome [8,9]. Hantaviruses are conventionally divided into the Old World and the New World hantaviruses based on the geographic regions where they occur, although phylogenetic tree based on the genomic RNA sequences forms three main groups, Hantaan virus-like viruses, Puumala virus-like viruses and Sin Nombre virus (SNV) -like viruses [10]. The Old World hantaviruses, including Hantaan, Seoul, Dobrava and Puumala viruses which are seen throughout Europe and Asia, cause a human disease known as hemorrhagic fever with renal syndrome (HFRS) with more than 100,000 cases diagnosed annually. Clinically, HFRS is initially characterized by non-specific flu-like symptoms followed by thrombocytopenia, and a capillary leak syndrome with hemoconcentration. In severe cases renal failure and shock can develop. Mortality rates vary from approximately 1% to 15%, depending on the individual virus [11, 12]. The New World hantaviruses include SNV and Andes virus, and are seen in North, Central, and South America [11,12]. While these hantaviruses have likely existed in the Americas for many years, they were recognized as a cause of disease when the first outbreak of hantavirus pulmonary syndrome (HPS) occurred in the southwestern United States in 1993 [13,14]. HPS shares many characteristics with HFRS, including thrombocytopenia and a capillary leak syndrome. However, there are some differences. The pathology seen with Old World hantaviruses focuses on the kidneys, but the major target organ for the New World hantaviruses

Corresponding author: Masanori Terajima, Center for Infectious Disease and Vaccine Research, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, U.S.A., Telephone: 1-508-856-2886. Fax: 1-508-856-4890. e-mail: Masanori.Terajima@umassmed.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

is the lung. HPS cases progress to a severe degree more frequently than HFRS cases. After a prodromal phase similar to that of HFRS, patients very rapidly develop pulmonary edema, and shock, which often requires mechanical ventilation and/or extracorporeal membrane oxygenation [15], and the case fatality rate is approximately 35% (<http://www.cdc.gov/ncidod/diseases/hanta/hps/noframes/caseinfo.htm>). Thus the New World hantaviruses cause some of the most lethal acute viral infections known, and antiviral therapy or vaccines are not yet available. In autopsied cases, most SNV antigens are found in endothelial cells, especially alveolar endothelial cells; but some other cells are also positive for viral antigen, such as monocyte/macrophages [16].

There have been three hypotheses to explain the mechanisms of increased capillary permeability. (1) The attack of infected endothelial cells by virus-specific cytotoxic T lymphocytes (CTLs); (2) TNF- α production by infected monocyte/macrophages; and (3) the direct effect of viral infection on endothelial cell functions.

Both in vivo and in vitro observations suggest that SNV is in general not directly cytopathic to infected cells including endothelial cells [6,7,16,17], although there are papers reporting apoptosis in some human and primate cell lines, such as human embryonic kidney 293 cells and African green monkey kidney Vero E6 cells, infected with hantaviruses [18–21]. β_3 -integrin is a cellular receptor for human-pathogenic hantaviruses [22,23]. Since the ligation of endothelial $\alpha_v\beta_3$ -integrin increased transcapillary liquid flux [24], it was speculated that the virus- β_3 -integrin interaction might be the mechanism of increased capillary permeability [22, 23]. Infection of endothelial cells alone, however, failed to increase their permeability [6,7, 25]. Hantavirus infection did inhibit β_3 -integrin-directed migration of endothelial cells, which might contribute to hantavirus pathogenesis [26].

Mechanisms involving CTLs have been suggested by us [27–29] and others [30–32]. Lung tissues obtained at necropsy from HPS patients contain abundant large immunoblasts consisting of CD4⁺ and CD8⁺ T cells [16] [17], and high numbers of cytokine-producing cells including TNF- α , interleukine-2, and interferon (IFN) - γ [33], which could mediate capillary leakage. In addition, preliminary evidence suggests that, in SNV infection, the HLA-B*3501 allele is associated with increased risk for developing severe HPS, implying involvement of CD8⁺ T cells [34]. We demonstrated very high frequencies of SNV-specific CD8⁺ T cells detected by MHC class I/peptide tetramer staining in HPS patients' blood during acute illness, and the magnitude of virus-specific T cell responses was significantly higher in the patients with clinically severe HPS (patients who met clinical criteria requiring mechanical ventilation) than in patients with moderate disease (hospitalized but not requiring mechanical ventilation) [29]. We also showed that specific CTL recognized and increased the permeability of an immortalized HLA-matched human endothelial cell monolayer infected with SNV in transwell permeability assays [35]. These data suggest that SNV-specific CD8⁺ T cells contribute to the observed capillary leakage during HPS. Since infected lungs at autopsy had no obvious damage in endothelial cells [16] [17], capillary leakage is more likely to be caused by cytokine release than by endothelial cell lysis. Lysis of a small percentage of endothelial cells, which is difficult to detect in tissue sections, may be enough to cause capillary leakage, although bleeding is very rare in HPS.

A linkage between disease severity and MHC haplotype was also observed in patients with nephropathia epidemica (NE), a milder form of HFRS caused by Puumala virus infection. HLA-B8-DR3 extended haplotype was associated with severe outcome of the disease [36, 37], and HLA-B27 was associated with milder disease [38], implying involvement of CD8⁺ T cells in NE pathogenesis. In NE patients the kidney biopsies showed interstitial infiltration of lymphocytes, plasma cells, monocytes/macrophages, and polymorphonuclear leukocytes. An increased expression of cytokines including TNF- α and endothelial adhesion molecules was

observed [39]. Plasma TNF- α levels were also elevated [40], and urinary excretion of interleukin-6 correlates with proteinuria [41].

In laboratory mice infected with Hantaan virus, virus-specific CD8⁺ T cells, not neutralizing antibodies, were important for clearance of the virus [42] [43] [44]. These laboratory mice, as well as natural rodent reservoirs of hantaviruses, do not develop any disease similar to HPS or HFRS, suggesting in mice these virus-specific T cell are protective, not immunopathogenic. It is not understood why these rodents don't develop the disease. We should remember that there are many differences in the immune systems of humans and mice [45].

In transgenic mouse model of influenza infection, in which lung alveolar epithelial cells expressed influenza A virus hemagglutinin (HA), adoptive transfer of HA-specific CD8⁺ T cells into the HA-transgenic mice induced lung injury, which was mediated by TNF- α produced by the HA-specific CD8⁺ T cells and chemokines produced by alveolar epithelial cells attacked by the HA-specific CD8⁺ T cells [46] [47]. A similar mechanism may occur as a result of endothelial cell-CD8⁺ T cell interactions.

A series of experiments performed by transplantation immunologists, however, showed that, contrary to lung alveolar epithelial cells, endothelial cells were protected from humoral and cellular immune responses in laboratory mice [48,49]. Johnson et al. analyzed humoral and cellular immune responses against β -galactosidase (BG) protein expressed in the endothelial cells of transgenic mice. In theory immune responses against BG protein would not be induced in BG-transgenic mice in which BG should be tolerated. Infection with recombinant vaccinia virus encoding BG, however, induced humoral and cellular immune responses in the BG-transgenic mice at the same level as responses in wild type FVB mice (from which the BG-transgenic were generated), and, more surprisingly, these infected mice remained healthy. No damage was observed in endothelial cells. The BG-transgenic mice also remained healthy after primed spleen cells or lymph node cells from immunized, wild type FVB mice, which contained CD8⁺ (and CD4⁺) T cells reacting to BG protein, were adoptively transferred into them. These results are surprising, but, nevertheless consistent with the down-regulation of CD8⁺ T cell activation and cytotoxicity by PD-L (PD-1 ligand) 1 and PD-L2 molecules expressed on IFN- γ -activated endothelial cells both in humans (in vitro study) and mice [50–52] (CD8⁺ T cells express programmed death-1 (PD-1) molecule).

To reconcile these two findings, the immunopathological mechanisms we would like to propose are:

1. In HPS and HFRS patients the mechanisms to down-regulate CD8⁺ T cell activation and cytotoxicity for protection of endothelial cells may be overwhelmed by the excess amount of activated CD8⁺ T cells, which appears to occur in HPS [29].
2. The protecting mechanisms may not be functioning properly because of the infection of endothelial cells. Glycoproteins of human pathogenic hantaviruses have been found to have immunomodulatory functions [53] [54], although the effects of hantavirus infection on PD-1, PD-L1 or PD-L2 are not known. It is also not known whether T cells are infected with hantavirus in vivo.

These two mechanisms can work synergistically, and infected monocyte/macrophages also can contribute to the immunopathogenesis by TNF- α production [6,25]. Involvement of virus-specific CD4⁺ T cells is also likely, although there are no data suggesting the direct role of CD4⁺ T cells in HPS or HFRS. Recently Salazar et al. reported that HLA-B35 molecule, a risk factor for severe HPS, increased susceptibility of cells to apoptosis [55].

In conclusion, we hypothesize that impairment of endothelial cell's defense mechanisms against cytotoxic CD8⁺ T cells is the mechanism of capillary leakage in HPS and HFRS, which

may be common to other viral hemorrhagic fevers. Immunopathological mechanisms are speculated to underlie diseases caused by dengue virus and arenavirus infections [2,56]. CD8⁺ T cells may be a potential target for therapy of some viral hemorrhagic fevers.

References

1. Peters, CJ. Viral Hemorrhagic Fevers. In: Nathanson, N., editor. *Viral Pathogenesis*. Philadelphia: Lippincott-Raven; 1997. p. 779-799.
2. Peters CJ, Zaki SR. Role of the endothelium in viral hemorrhagic fevers. *Crit Care Med* 2002;30:S268–S273. [PubMed: 12004247]
3. Schnittler HJ, Mahner F, Drenckhahn D, Klenk HD, Feldmann H. Replication of Marburg virus in human endothelial cells. A possible mechanism for the development of viral hemorrhagic disease. *J Clin Invest* 1993;91:1301–1309. [PubMed: 8473483]
4. Yanagihara R, Silverman DJ. Experimental infection of human vascular endothelial cells by pathogenic and nonpathogenic hantaviruses. *Arch Virol* 1990;111:281–286. [PubMed: 2112908]
5. Pensiero MN, Sharefkin JB, Dieffenbach CW, Hay J. Hantaan virus infection of human endothelial cells. *J Virol* 1992;66:5929–5936. [PubMed: 1356160]
6. Khaiboullina SF, Netski DM, Krumpke P, St Jeor SC. Effects of tumor necrosis factor alpha on Sin Nombre virus infection In vitro. *J Virol* 2000;74:11966–11971. [PubMed: 11090198]
7. Sundstrom JB, McMullan LK, Spiropoulou CF, Hooper WC, Ansari AA, Peters CJ, et al. Hantavirus infection induces the expression of RANTES and IP-10 without causing increased permeability in human lung microvascular endothelial cells. *J Virol* 2001;75:6070–6085. [PubMed: 11390609]
8. Schmaljohn, CS.; Hooper, JW. *Bunyaviridae: The Viruses and Their Replication*. In: Knipe, DM.; Howley, PM., editors. *Fields Virology*. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1581-1602.
9. Nichol, ST. Bunyaviruses. In: Knipe, DM.; Howley, PM., editors. *Fields Virology*. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 1603-1633.
10. Plyusnin A. Genetics of hantaviruses: implications to taxonomy. *Arch Virol* 2002;147:665–682. [PubMed: 12038679]
11. Schmaljohn C, Hjelle B. Hantaviruses: a global disease problem. *Emerg Infect Dis* 1997;3:95–104. [PubMed: 9204290]
12. Peters CJ, Simpson GL, Levy H. Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. *Annu Rev Med* 1999;50:531–545. [PubMed: 10073292]
13. Khan AS, Young JC. Hantavirus pulmonary syndrome: at the crossroads. *Curr Opin Infect Dis* 2001;14:205–209. [PubMed: 11979134]
14. Peters CJ, Khan AS. Hantavirus pulmonary syndrome: the new American hemorrhagic fever. *Clin Infect Dis* 2002;34:1224–1231. [PubMed: 11941549]
15. Koster, FT.; Jenison, SA. Hantaviruses. In: Gorbach, SL.; Bartlett, JG.; Blacklow, NR., editors. *Infectious Diseases*. Philadelphia: WB Saunders; 1997.
16. Zaki SR, Greer PW, Coffield LM, Goldsmith CS, Nolte KB, Foucar K, et al. Hantavirus pulmonary syndrome. Pathogenesis of an emerging infectious disease. *Am J Pathol* 1995;146:552–579. [PubMed: 7887439]
17. Nolte KB, Feddersen RM, Foucar K, Zaki SR, Koster FT, Madar D, et al. Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. *Hum Pathol* 1995;26:110–120. [PubMed: 7821907]
18. Kang JI, Park SH, Lee PW, Ahn BY. Apoptosis is induced by hantaviruses in cultured cells. *Virology* 1999;264:99–105. [PubMed: 10544134]
19. Li XD, Kukkonen S, Vapalahti O, Plyusnin A, Lankinen H, Vaheri A. Tula hantavirus infection of Vero E6 cells induces apoptosis involving caspase 8 activation. *J Gen Virol* 2004;85:3261–3268. [PubMed: 15483239]
20. Li XD, Lankinen H, Putkuri N, Vapalahti O, Vaheri A. Tula hantavirus triggers pro-apoptotic signals of ER stress in Vero E6 cells. *Virology* 2005;333:180–189. [PubMed: 15708603]

21. Markotic A, Hensley L, Geisbert T, Spik K, Schmaljohn C. Hantaviruses induce cytopathic effects and apoptosis in continuous human embryonic kidney cells. *J Gen Virol* 2003;84:2197–2202. [PubMed: 12867652]
22. Gavrilovskaya IN, Shepley M, Shaw R, Ginsberg MH, Mackow ER. beta3 Integrins mediate the cellular entry of hantaviruses that cause respiratory failure. *Proc Natl Acad Sci U S A* 1998;95:7074–7079. [PubMed: 9618541]
23. Gavrilovskaya IN, Brown EJ, Ginsberg MH, Mackow ER. Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by beta3 integrins. *J Virol* 1999;73:3951–3959. [PubMed: 10196290]
24. Tsukada H, Ying X, Fu C, Ishikawa S, McKeown-Longo P, Albelda S, et al. Ligation of endothelial alpha v beta 3 integrin increases capillary hydraulic conductivity of rat lung. *Circ Res* 1995;77:651–659. [PubMed: 7554109]
25. Niikura M, Maeda A, Ikegami T, Saijo M, Kurane I, Morikawa S. Modification of endothelial cell functions by Hantaan virus infection: prolonged hyper-permeability induced by TNF-alpha of hantaan virus-infected endothelial cell monolayers. *Arch Virol* 2004;149:1279–1292. [PubMed: 15221531]
26. Gavrilovskaya IN, Peresleni T, Geimonen E, Mackow ER. Pathogenic hantaviruses selectively inhibit beta3 integrin directed endothelial cell migration. *Arch Virol* 2002;147:1913–1931. [PubMed: 12376753]
27. Ennis FA, Cruz J, Spiropoulou CF, Waite D, Peters CJ, Nichol ST, et al. Hantavirus pulmonary syndrome: CD8+ and CD4+ cytotoxic T lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness. *Virology* 1997;238:380–390. [PubMed: 9400611]
28. Terajima M, Vapalahti O, Van Epps HL, Vaheiri A, Ennis FA. Immune responses to Puumala virus infection and the pathogenesis of nephropathia epidemica. *Microbes Infect* 2004;6:238–245. [PubMed: 15049335]
29. Kilpatrick ED, Terajima M, Koster FT, Catalina MD, Cruz J, Ennis FA. Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. *J Immunol* 2004;172:3297–3304. [PubMed: 14978138]
30. Khaiboullina SF, St Jeor SC. Hantavirus immunology. *Viral Immunol* 2002;15:609–625. [PubMed: 12513931]
31. Maes P, Clement J, Gavrilovskaya I, Van Ranst M. Hantaviruses: immunology, treatment, and prevention. *Viral Immunol* 2004;17:481–497. [PubMed: 15671746]
32. Borges AA, Campos GM, Moreli ML, Souza RL, Aquino VH, Saggiaro FP, et al. Hantavirus cardiopulmonary syndrome: immune response and pathogenesis. *Microbes Infect* 2006;8:2324–2330. [PubMed: 16793309]
33. Mori M, Rothman AL, Kurane I, Montoya JM, Nolte KB, Norman JE, et al. High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. *J Infect Dis* 1999;179:295–302. [PubMed: 9878011]
34. Koster F, Vigil J, Olson D, Terajima M, Ennis F, Moehenkamp C, et al. Class I, II and III HLA alleles associated with severe hantavirus cardiopulmonary syndrome in the southwest US (meeting abstract). *Am J Trop Med* 2001;65:152.
35. Hayasaka D, Maeda K, Ennis FA, Terajima M. Increased permeability of human endothelial cell line EA.hy926 induced by hantavirus-specific cytotoxic T lymphocytes. *Virus Res* 2007;123:120–127. [PubMed: 16979772]
36. Mustonen J, Partanen J, Kanerva M, Pietila K, Vapalahti O, Pasternack A, et al. Genetic susceptibility to severe course of nephropathia epidemica caused by Puumala hantavirus. *Kidney Int* 1996;49:217–221. [PubMed: 8770970]
37. Makela S, Mustonen J, Ala-Houhala I, Hurme M, Partanen J, Vapalahti O, et al. Human leukocyte antigen-B8-DR3 is a more important risk factor for severe Puumala hantavirus infection than the tumor necrosis factor-alpha(-308) G/A polymorphism. *J Infect Dis* 2002;186:843–846. [PubMed: 12198621]
38. Mustonen J, Partanen J, Kanerva M, Pietila K, Vapalahti O, Pasternack A, et al. Association of HLA B27 with benign clinical course of nephropathia epidemica caused by Puumala hantavirus. *Scand J Immunol* 1998;47:277–279. [PubMed: 9519867]

39. Temonen M, Mustonen J, Helin H, Pasternack A, Vaheri A, Holthofer H. Cytokines, adhesion molecules, and cellular infiltration in nephropathia epidemica kidneys: an immunohistochemical study. *Clin Immunol Immunopathol* 1996;78:47–55. [PubMed: 8599883]
40. Linderholm M, Ahlm C, Settergren B, Waage A, Tarnvik A. Elevated plasma levels of tumor necrosis factor (TNF)-alpha, soluble TNF receptors, interleukin (IL)-6, and IL-10 in patients with hemorrhagic fever with renal syndrome. *J Infect Dis* 1996;173:38–43. [PubMed: 8537680]
41. Makela S, Mustonen J, Ala-Houhala I, Hurme M, Koivisto AM, Vaheri A, et al. Urinary excretion of interleukin-6 correlates with proteinuria in acute Puumala hantavirus-induced nephritis. *Am J Kidney Dis* 2004;43:809–816. [PubMed: 15112171]
42. Araki K, Yoshimatsu K, Lee BH, Kariwa H, Takashima I, Arikawa J. Hantavirus-specific CD8(+)-T-cell responses in newborn mice persistently infected with Hantaan virus. *J Virol* 2003;77:8408–8417. [PubMed: 12857910]
43. Araki K, Yoshimatsu K, Lee BH, Kariwa H, Takashima I, Arikawa J. A new model of Hantaan virus persistence in mice: the balance between HTNV infection and CD8(+) T-cell responses. *Virology* 2004;322:318–327. [PubMed: 15110529]
44. Araki K, Yoshimatsu K, Lee BH, Okumura M, Kariwa H, Takashima I, et al. Age-dependent hantavirus-specific CD8(+) T-cell responses in mice infected with Hantaan virus. *Arch Virol* 2004;149:1373–1382. [PubMed: 15221537]
45. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. *J Immunol* 2004;172:2731–2738. [PubMed: 14978070]
46. Zhao MQ, Stoler MH, Liu AN, Wei B, Soguero C, Hahn YS, et al. Alveolar epithelial cell chemokine expression triggered by antigen-specific cytolytic CD8(+) T cell recognition. *J Clin Invest* 2000;106:R49–R58. [PubMed: 10995793]
47. Xu L, Yoon H, Zhao MQ, Liu J, Ramana CV, Enelow RI. Cutting edge: pulmonary immunopathology mediated by antigen-specific expression of TNF-alpha by antiviral CD8+ T cells. *J Immunol* 2004;173:721–725. [PubMed: 15240656]
48. Rothermel AL, Wang Y, Schechner J, Mook-Kanamori B, Aird WC, Pober JS, et al. Endothelial cells present antigens in vivo. *BMC Immunol* 2004;5:5. [PubMed: 15113397]
49. Johnson DR. Endothelial Cell-mediated Antigen Presentation. *Transfusion Medicine and Hemotherapy* 2006;33:58–70.
50. Rodig N, Ryan T, Allen JA, Pang H, Grabie N, Chernova T, et al. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytotoxicity. *Eur J Immunol* 2003;33:3117–3126. [PubMed: 14579280]
51. Mazanet MM, Hughes CC. B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis. *J Immunol* 2002;169:3581–3588. [PubMed: 12244148]
52. Eppihimer MJ, Gunn J, Freeman GJ, Greenfield EA, Chernova T, Erickson J, et al. Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. *Microcirculation* 2002;9:133–145. [PubMed: 11932780]
53. Alff PJ, Gavrilovskaya IN, Gorbunova E, Endriss K, Chong Y, Geimonen E, et al. The pathogenic NY-1 hantavirus G1 cytoplasmic tail inhibits RIG-I and TBK-1-directed interferon responses. *J Virol* 2006;80:9676–9686. [PubMed: 16973572]
54. Spiropoulou CF, Albarino CG, Ksiazek TG, Rollin PE. Andes and Prospect Hill hantaviruses differ in early induction of interferon although both can downregulate interferon signaling. *J Virol* 2007;81:2769–2776. [PubMed: 17202220]
55. Salazar G, Colombo G, Lenna S, Antonioli R, Beretta L, Santaniello A, et al. HLA-B35 influences the apoptosis rate in human peripheral blood mononucleated cells and HLA-transfected cells. *Hum Immunol* 2007;68:181–191. [PubMed: 17349873]
56. Rothman AL, Ennis FA. Immunopathogenesis of Dengue hemorrhagic fever. *Virology* 1999;257:1–6. [PubMed: 10208914]